News
July 25, 2019
Obsidian Therapeutics Announces Strengthening of Executive Leadership Team Expanded Leadership Supports Company Evolution into Development-Stage Biotechnology Company using cytoDRiVE™ Technology to Regulate Cell and Gene Therapies […]
April 18, 2019
Obsidian Therapeutics Announces Leadership Transition and Appoints Paul K. Wotton, Ph.D., as Chief Executive Officer Experienced CEO brings expertise in product development, cell and gene therapies, […]
January 18, 2019
Obsidian Therapeutics Announces Strategic Collaboration with Celgene to Develop Novel Cell Therapies with Tunable Immunomodulatory Factors, Opening Potential for CAR-T and Other Cellular Medicines in New […]
December 6, 2017
Obsidian Therapeutics Announces $49.5 Million Series A Financing to Develop Controllable Cell and Gene Therapy Products Financing led by GV to focus on lead programs for […]